References
- Hayes JR, Born GF, Rosenbaum AH. Incidence of orthostatic hypotension in patients with primary affective disorders treated with tricyclic antidepressants. Mayo Clin Proc 1977; 52: 509–12
- Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34: 197–204
- Thayssen P, Bjerre M, Kragh-Sorensen P, Moller M, Petersen OL, Kristensen CB, et al. Cardiovascular effect of imipramine and nortriptyline in elderly patients. Psychopharmacology Berl 1981; 74: 360–4
- Moller M, Thayssen P, Kragh-Sorensen P, Pedersen OL, Kristensen CB, Bjerre M, et al. Mianserin: Cardiovascular effects in elderly patients. Psychopharmacology Berl 1983; 80: 174–7
- Stage KB, Bech P, Kragh-Sorensen P. Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand 2002; 105: 55–9
- Glassman AH, Bigger JJ, Giardina EV, Kantor SJ, Perel JM, Davies M. Clinical characteristics of imipramine-induced orthostatic hypotension. Lancet 1979; 1: 468–72
- Tang SW, Seeman P. Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 1980; 311: 255–61
- Hall H, Ogren SO. Effects of antidepressant drugs on different receptors in the brain. Eur J Pharmacol 1981; 70: 393–407
- Koczkas C, Holm P, Karlsson A, Nagy A, Ose E, Petursson H, et al. Moclobemide and clomipramine in endogenous depression. A randomized clinical trial. Acta Psychiatr Scand 1989; 79: 523–9
- Larsen JK, Holm P, Mikkelsen PL. Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial. Acta Psychiatr Scand 1984; 70: 254–60
- Newburn GM, Fraser AR, Menkes DB, Mullen PE. A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders. Aust N Z J Psychiatry 1990; 24: 475–9
- Delini-Stula A, Baier D, Kohnen R, Laux G, Philipp M, Scholz HJ. Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor–results of the drug utilization observation studies. Pharmacopsychiatry 1999; 32: 61–7
- Danish University Antidepressant Group. Moclobemide: A reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105–16.
- Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278–96
- Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1–100
- Gram LF, Brosen K. Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group. Br J Clin Pharmacol 1993; 35: 649–52
- Nielsen KK, Brosen K, Gram LF. Steady-state plasma levels of clomipramine and its metabolites: Impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group. Eur J Clin Pharmacol 1992; 43: 405–11
- Christensen P, Thomsen HY, Pedersen OL, Gram LF, Kragh-Sørensen P. Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology 1985; 86: 383–5
- Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998; 351: 1303–7
- Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001; 23: 435–40